Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Viking Therapeutics. The associated price target remains the same with $102.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors, including the strong enrollment completion of the VANQUISH-1 trial, which exceeded its target size ahead of schedule. This indicates a robust demand for Viking Therapeutics’ VK2735, particularly in its subcutaneous form for patients with obesity or overweight conditions.
Additionally, the promising strategy for oral VK2735, which aims to balance effective weight loss with manageable dosing and pill size, further supports the positive outlook. The upcoming end-of-Phase 2 FDA meeting and the potential for a favorable commercial position if Phase 3 data are consistent with current findings contribute to the stock’s potential upside.